AMCP Joins Pharmaceutical Supply Chain Stakeholders to Support Access to Medications; AMCP Comments on COVID-19 Changes to Medicare Program; FDA Issues RFI on Improving the Orange Book; CMS Issues Final Medicare Part C and Part D Policy, Technical Rule
May issue includes: AMCP Submits Comments on Proposed Part D MTM Program CMR Changes; AMCP Submits Comments on Proposed Part D MTM Program CMR Changes; Two Proposed Biosimilars Bills Fail to Advance
April issue includes: CARES Act Includes Changes Relevant to Managed Care Pharmacy, Substance Abuse Record Rules; HHS Authorizes Pharmacists to Order and Administer COVID19 Tests; AMCP Launches COVID19 Resource Center; AMCP Submits Comments on Proposed Medicare Advantage and Part D Rule; AMCP Comments to FDA and FTC on a Competitive Biosimilar Marketplace
March 2020 Legislative & Regulatory Briefing: Articles include CMS Issues Contract Year 2021 and 2022 Medicare Advantage and Part D Proposed Rule; AMCP Shares CMS Resources for COVID-19 Response; AMCP Submits Comments on Drug Importation on Proposals
AMCP Develops 2020 Policy and Advocacy Focus Areas; CMS Issues CY 2021 Advanced Notice for MA Capitation Rates and Part C and Part D Payment Policies – Part II; CMS Issues CY 2021 and 2022 Medicare Advantage and Part D Proposed Rule; CMS Releases New Guidance on Medicaid Waiver Flexibility
AMCP Submits Comments to HHS OIG on Proposed Revisions to AKS Safe Harbors; AMCP to Comment on White House Proposal to Allow Drug Importation; FDA Issues Draft Guidance on Interchangeable Insulin; AMCP Invited to Participate in Pharmaceutical Quality Workshop
Trump Administration Issues Proposed Rule Allowing Importation; House Passes H.R. 3 Drug Pricing Bill on Party-Line Vote; AMCP Submits Letter to House on 21st Century Cures 2.0; Stephen Hahn, MD, Confirmed as New FDA Commissioner; FDA Issues Draft Guidance on Interchangeable Insulin
